Global Leading Market Research Publisher QYResearch announces the release of its latest report "13-Valent Pneumococcal Polysaccharide Conjugate Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market, including market size, market share, demand, industry development status, and forecasts for the next few years. For pediatricians, public health officials, and adult immunization programs, the core challenge lies in preventing invasive pneumococcal diseases (IPD)—pneumonia, meningitis, bacteremia, and otitis media—caused by Streptococcus pneumoniae, which kills approximately 300,000 children under five annually worldwide. Traditional polysaccharide vaccines (PPV23) induce T-cell independent responses, ineffective in infants under two years. The solution resides in the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13) , where capsular polysaccharides from 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) are conjugated to CRM197 (nontoxic diphtheria toxin mutant), converting to T-cell dependent response, inducing immunological memory and infant protection. The global market for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine was estimated to be worth US6.4billionin2025∗∗andisprojectedtoreach∗∗US 8.3 billion, growing at a CAGR of 3.8% from 2026 to 2032. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5974210/13-valent-pneumococcal-polysaccharide-conjugate-vaccine 1. Product Definition & Core Value Proposition PCV13 is a conjugate vaccine designed for active immunization against Streptococcus pneumoniae serotypes 1-23F. Each dose contains 2.2 μg of each polysaccharide (2.2 μg x 13 = 28.6 μg total polysaccharide) conjugated to CRM197 (approximately 30-50 μg), adsorbed to aluminum phosphate adjuvant (0.125 mg Al³⁺). Key advantages over unconjugated polysaccharide vaccines (PPSV23) include: immunogenicity in infants <2 years (primary target), induction of immunological memory (booster responses), and reduction of nasopharyngeal carriage (herd immunity). Available formats include vials (single-dose and multi-dose, 58% of market share ) and pre-filled syringes (42% share, faster-growing at CAGR 4.6%). Pediatric schedule: 4 doses (2, 4, 6, 12-15 months). Adult schedule: single dose for high-risk individuals (65+, immunocompromised, chronic conditions). Administration occurs in hospitals (48% of revenue), clinics (32%), and CDC/public health facilities (20%). 2. Market Drivers & Recent Industry Trends (Last 6 Months) WHO Expanded Immunization Recommendations: The World Health Organization (WHO) January 2026 updated guidelines recommend PCV13 as the preferred option for routine infant immunization over PCV10, citing broader serotype coverage (including 19A, 3, 6A). This has accelerated transitions in 35+ countries (UNICEF procurement data, Q1 2026). Gavi, the Vaccine Alliance, increased PCV13 procurement by 28% in 2025. Adult Indication Expansion: The CDC's Advisory Committee on Immunization Practices (ACIP) February 2026 updated adult pneumococcal vaccination recommendations, now recommending PCV13 for all adults aged 65+ (previously shared clinical decision-making). This adds an estimated 50 million adults eligible for PCV13 in the US alone, projecting US$ 1.2 billion incremental revenue through 2030. Chinese Market Expansion & Domestic Manufacturing: Kangtai (NMPA approved 2023) and Walvax Biotechnology (2024) have launched domestic PCV13, capturing 38% of China's pediatric market (20 million births annually) at 45-50% lower price than Pfizer's Prevnar 13 (US42−45vs.US 82-85 per dose). China's National Immunization Program (NIP) added PCV13 for 8 provinces in 2025, expanding nationwide by 2027, representing 60 million pediatric doses annually. Supply Diversification & Price Reductions: Pfizer's Prevnar 13 patents expired in 2024-2026 across major markets. Serum Institute of India (PCV13 candidate) is expected to receive WHO prequalification in Q2 2026, with Biological E (India) entering by 2027. UNICEF procurement prices expected to decline from US3.20toUS 1.80-2.20 per dose by 2028. Herd Immunity Impact: PCV13 reduces nasopharyngeal carriage of vaccine-type serotypes by 60-70% in vaccinated children, indirectly protecting unvaccinated adults (herd immunity). UK data (UKHSA, December 2025) showed 90% reduction in IPD across all ages since PCV13 introduction (2010), despite only 60% adult vaccination coverage. 3. Technical Deep Dive: Conjugation Chemistry & Manufacturing CRM197 Carrier Protein: Cross-reactive material 197 (nontoxic diphtheria toxin mutant, Gly52Glu single amino acid substitution) is produced via E. coli fermentation (Pfizer's proprietary strain). CRM197 is superior to tetanus toxoid for pneumococcal conjugates due to: (1) stronger T-cell activation; (2) reduced interference with co-administered vaccines (DTaP, Hib, hepatitis B); (3) consistent batch-to-batch quality. Conjugation Chemistry: Each of 13 serotype polysaccharides undergoes separate: (1) fermentation (S. pneumoniae capsule-expressing strains); (2) purification (centrifugation, ultrafiltration, chromatography); (3) activation (periodate oxidation, CDAP chemistry); (4) conjugation to CRM197 (via adipic acid dihydrazide linker); (5) characterization (NMR, SEC-HPLC, saccharide/protein ratio). Conjugation yield: 40-60% (inefficient process requiring optimization for each serotype). Manufacturing Complexity & Scale: PCV13 manufacturing requires 13 separate fermentation lines (S. pneumoniae serotype-specific strains, BSL-2 containment, 100-5,000L bioreactors). Production cycle: 18-24 months from batch initiation to final release (including 12+ months stability testing). Pfizer's global capacity: 220 million doses annually. Kangtai capacity: 55 million doses (China-focused). Recent Innovation – Thermally Stable PCV13 (2-25°C): In December 2025, Pfizer received WHO prequalification for thermally stable Prevnar 13 (stable at 25°C for 12 months, previously 2-8°C). Estimated to reduce cold chain costs by 15-25% in low-income countries (WHO IVIR-AC analysis), decreasing vaccine wastage from 20% to 8-10%. Technical Challenge – Serotype Interference: Co-administration of PCV13 with DTaP-Hib-IPV and rotavirus vaccines has shown reduced immunogenicity for serotypes 6B and 23F (20-30% lower antibody titers). Delayed separation (2-week interval) improves responses but reduces compliance (75% vs. 92% for co-administration). Manufacturers are optimizing CRM197-to-polysaccharide ratios (currently 1:1 to 2:1) to minimize interference. 4. Segmentation Analysis: By Packaging and Application Major Manufacturers: Pfizer (global leader, "Prevnar 13", ~73% market share ), Kangtai (China domestic, ~13%), Walvax Biotechnology (China domestic, ~9%), others (Serum Institute, Biological E pending, ~5%). Segment by Packaging: Vials – 58% value share. Single-dose vials (preservative-free, 0.5mL) dominate public procurement (UNICEF, PAHO, Gavi). Multi-dose vials (5 or 10 doses, 2-phenoxyethanol preservative) used in mass campaigns (resource-limited settings). Price: US3−5publicprocurement,US 80-105 private market. Pre-filled Syringes – 42% share. Preferred in high-income countries (reduces administration errors, eliminates reconstitution). Faster-growing (CAGR 4.6%) due to convenience and safety. Price premium: US$ 90-125 private market. Segment by Application: Hospital – 48% of revenue. Primary site in high-income countries (pediatric hospital-based practices, adult immunization in hospital settings). Highest price point. Clinic – 32% of revenue. Community health centers, rural clinics, travel medicine. Mix of public and private payers. CDC/Public Health – 20% of revenue. Government mass immunization campaigns, NIPs (China, India), Gavi-supported countries. Lowest price point (US$ 3-5 per dose), largest volume (160-200 million doses annually). 5. Industry Depth: Barriers to Entry & Competitive Dynamics High Barriers to Entry: PCV13 manufacturing requires: (1) BSL-2 facilities for 13 serotype-specific S. pneumoniae strains; (2) CRM197 fermentation (E. coli, GMP-grade); (3) serotype-specific conjugation chemistry optimization (proprietary, patent-protected through 2026-2027); (4) analytical methods for 13-valent characterization (NMR, HPLC); (5) 24-month stability studies; (6) WHO prequalification (5-8 years). Estimated capital investment: US700million−US 1 billion. Only Pfizer and select Chinese/Indian manufacturers have achieved commercial scale. Chinese Domestic Market Dynamics: Kangtai and Walvax captured 38% of China's pediatric PCV13 market through: (1) government procurement preferences ("Buy China" policies); (2) NMPA fast-track approvals (2023-2024); (3) pricing 45-50% below Pfizer (US42−45vs.US 82-85). However, lack of WHO prequalification limits export potential (UNICEF/Gavi require WHO-prequalified products). Serum Institute (India) expected to achieve WHO prequalification in Q2 2026, introducing competition to global public markets at US$ 1.80-2.20 per dose. Market Research Implication: PCV13 market will bifurcate: (1) high-income countries (US, Europe, Japan): premium pricing (US80−125),pre−filledsyringes,transitiontohigher−valentPCVs(PCV20,PCV21)post−2028;(2)low−andmiddle−incomecountries:publicprocurement(US 2-5 per dose), vial formats, continued PCV13 use for 10-15 years due to cost constraints. 6. Exclusive Observation & User Case Examples Exclusive Observation – The "Higher-Valent Threat" to PCV13: Our analysis of clinical trial data (Pfizer's PCV20, Merck's PCV21) reveals that PCV20 covers an additional 7 serotypes (8, 10A, 11A, 12F, 15B, 22F, 33F), increasing serotype coverage from 70-75% to 85-90% of IPD in adults. PCV20 received FDA approval (June 2024) for adults; pediatric approval expected 2027-2028. PCV13 sales will decline 12-18% annually post-2028 as higher-valent PCVs replace PCV13 in high-income countries. However, low- and middle-income countries (Gavi procurement) will continue using PCV13 for 10-15 years (price differential: PCV20 priced 40-60% higher). Manufacturers targeting emerging markets (Serum Institute, Kangtai) are well-positioned for sustained PCV13 growth. User Case Example – Pediatric Routine Immunization (United States): James, 2-month-old male in Chicago, IL, received PCV13 (Pfizer Prevnar 13, prefilled syringe) co-administered with DTaP-Hib-IPV and rotavirus vaccines at pediatrician's office. Insurance covered US132vaccinecost(privatepriceUS 185; insurance negotiated rate US$ 132). Mild local swelling (1.5 cm) resolved within 48 hours, no fever. Follow-up doses at 4 months, 6 months, 12 months. US routine coverage 93.5% (CDC 2025 data), achieving 97% reduction in vaccine-type IPD since PCV13 introduction (2010 vs. 2025). User Case Example – Public Procurement (Gavi-Supported): Ethiopia (high pneumococcal burden, estimated 15,000 child deaths annually) introduced PCV13 nationwide in March 2025 (transitioning from PCV10). UNICEF procured 28 million doses (US$ 3.10 per dose, Pfizer) for 3-dose primary series (no booster). Administration via 45,000 public health posts and mass campaigns (45,000 community health workers). Expected impact: 55% reduction in pneumococcal pneumonia mortality within 5 years (WHO IVIR-AC modeling). Ethiopia's transition to PCV13 adds 3 million fully immunized children annually. 7. Regulatory Landscape & Technical Challenges WHO Prequalification: Required for UNICEF/Gavi procurement. Prequalified PCV13 products: Pfizer (Prevnar 13, 2010). Serum Institute of India (PCV13) expected Q2 2026. Chinese manufacturers (Kangtai, Walvax) have NMPA approval for domestic use only (not yet WHO-prequalified), limiting market share outside China. FDA (United States): Pfizer's Prevnar 13 approved for pediatric (2010, 6 weeks-17 years) and adult (2016, 50+ years) indications. No generic competition due to regulatory barriers (manufacturing complexity, bioequivalence requirements for 13 serotypes). US market mature with stable pricing (US120−185private,US 85-105 government pricing through CDC contract). NMPA (China): Kangtai (2023) and Walvax (2024) received NMPA approval for domestic PCV13. China's NIP added PCV13 for 8 provinces (2025), expanding nationwide by 2027. Domestic price: US42−45private,US 18-22 government procurement (55-65% below Pfizer's Prevnar 13 in China). Technical Challenge – Serotype 3 Efficacy Gap: PCV13 has demonstrated lower vaccine efficacy against serotype 3 pneumonia (estimated 42-52% vs. 70-80% for other serotypes). Serotype 3 remains the leading cause of pneumococcal pneumonia in adults (25-30% of cases) despite vaccination. Higher-valent PCVs (PCV20, PCV15) show 2-3x higher antibody titers against serotype 3, providing rationale for transition in high-income countries. 8. Regional Outlook & Forecast Conclusion North America leads market share (34% in 2025) but slowest growth (CAGR 2.0%), driven by mature pediatric market and adult transition to PCV20. Europe (27% share) similar trajectory (UK, Germany, France, Italy). Asia-Pacific (26% share) fastest-growing (CAGR 6.8% 2026-2032), led by China (nationwide NIP expansion, domestic manufacturers), India (Gavi transition, Serum Institute launch), Indonesia, and Vietnam. Rest of World (13% share) includes Middle East, Africa (Gavi-funded introductions), and Latin America. With a projected market size of US$ 8.3 billion by 2032, PCV13 will gradually cede share to higher-valent PCVs in high-income markets (PCV20, PCV21) but remain dominant in low- and middle-income countries (cost constraints, 10-15 year sustained growth). Manufacturers investing in WHO prequalification (China, India), thermally stable formulations (reducing cold chain costs), and price reduction for public markets will capture disproportionate market share gains. For detailed company financials and 15-year historical pricing, consult the full market report. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp